# A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus

> **NCT01283139** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 834 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Sifalimumab 200 mg
- **BIOLOGICAL:** Sifalimumab 600 mg
- **BIOLOGICAL:** Sifalimumab 1,200 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01283139
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-31
- **Primary completion:** 2013-11-14
- **Final completion:** 2014-04-17
- **Target enrollment:** 834 (ACTUAL)
- **Last updated:** 2018-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01283139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01283139, "A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01283139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*